...
首页> 外文期刊>Cardiology Research >Thrombolysis Is an Effective and Safe Therapy in Stuck Mitral Valves With Delayed Presentation as Well as Hemodynamically Unstable Patients: A Single Centre Study
【24h】

Thrombolysis Is an Effective and Safe Therapy in Stuck Mitral Valves With Delayed Presentation as Well as Hemodynamically Unstable Patients: A Single Centre Study

机译:单项中心研究显示,溶栓治疗对于延迟出现的二尖瓣和血流动力学不稳定的患者是一种有效且安全的治疗方法

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Thrombosis is a complication of prosthetic valves on oral anticoagulants which is associated with significant morbidity and mortality. A re-operation carries a substantial risk, with mortality rate from 10% to 15% in selected series, which may be 2- or 3-folds higher in critically ill patients. This study conducted in a tertiary care cardiology unit aimed to evaluate the effectiveness and safety of thrombolytic therapy in stuck mitral bileaflet heart valves.Methods: As a prospective observational study, clinical symptoms and fluoroscopy were the mainstay in diagnosis of stuck mitral valve. Gradient across the valve by transthoracic echocardiography was used to monitor the therapy every 6 h. Fall of mean gradient more than 50% was considered as successful thrombolysis. And final results were again checked by fluoroscopy with documentation of improved leaflet movement.Results: Totally we studied 34 patients. Patients receiving thrombolytic therapy with streptokinase achieved an overall 91.2% freedom from a repeat operation or major complications, a large subcutaneous hematoma occurred in one ( 2.9%), reoperation required in two due to failure of treatment (5.9%), allergic reaction in one (2.9%), one patient developed transient neurologic dysfunction (2.9%) and one patient died during therapy due to refractory cardiogenic shock(2.9%). All patients including those with delayed presentation (> 14 days) and hemodynamically unstable patients had good results similar to those who presented within 14 days and hemodynamically stable. Mortality was higher in unstable patients and reoperation was higher with delayed presentation.Conclusions: Thrombolysis with streptokinase is highly successful and safe therapy in hemodynamically stable as well as unstable patients, or those with early or delayed presentation with stuck bileaflet mitral valves, especially in centers where round the clock cardiothoracic surgery backup is not available.Cardiol Res. 2018;9(3):161-164doi: https://doi.org/10.14740/cr708w.
机译:背景:血栓形成是口服抗凝剂上人工瓣膜的并发症,与明显的发病率和死亡率有关。再次手术会带来很大的风险,在选定的系列中,死亡率从10%到15%,对于重症患者,死亡率可能高2到3倍。这项研究是在三级心脏病学部门进行的,旨在评估溶栓治疗二尖瓣双瓣膜心脏瓣膜的有效性和安全性。方法:作为一项前瞻性观察性研究,临床症状和透视检查是诊断二尖瓣膜阻塞的主要手段。经胸超声心动图检查跨瓣的梯度每6小时监测一次治疗。平均梯度下降超过50%被认为是成功的溶栓治疗。并通过荧光检查再次检查了最终结果,并记录了改善的小叶运动。结果:我们共研究了34例患者。接受链激酶溶栓治疗的患者总体上没有重复手术或重大并发症的发生率达到91.2%,其中发生较大皮下血肿的一种(占2.9%),由于治疗失败而需要进行两次的再次手术(占5.9%),其中有过敏反应(2.9%),一名患者出现短暂性神经功能障碍(2.9%),一名患者在治疗期间因难治性心源性休克死亡(2.9%)。所有患者,包括延迟就诊(> 14天)和血流动力学不稳定的患者,均具有与14天以内就诊且血液动力学稳定的患者相似的良好结果。结论:链激酶的溶栓治疗在血流动力学稳定和不稳定的患者中,或在双叶瓣二尖瓣粘连早期或延迟出现的患者中,尤其在中心患者中,血栓栓塞酶治疗是非常成功和安全的治疗方法没有全天候心胸外科手术后备的地方。 2018; 9(3):161-164doi:https://doi.org/10.14740/cr708w。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号